Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.92 USD
Change Today +0.14 / 0.54%
Volume 148.5K
OMED On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

oncomed pharmaceuticals inc (OMED) Snapshot

Open
$25.61
Previous Close
$25.78
Day High
$25.98
Day Low
$24.58
52 Week High
04/1/14 - $34.75
52 Week Low
08/14/14 - $16.57
Market Cap
776.1M
Average Volume 10 Days
180.1K
EPS TTM
$-1.68
Shares Outstanding
29.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOMED PHARMACEUTICALS INC (OMED)

oncomed pharmaceuticals inc (OMED) Related Bloomberg News

View More Bloomberg News

oncomed pharmaceuticals inc (OMED) Related Businessweek News

No Related Businessweek News Found

oncomed pharmaceuticals inc (OMED) Details

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has completed preclinical trial that targets and inhibits DLL4 and vascular endothelial growth factor (VEGF); Tarextumab (Anti-Notch2/3, OMP-59R5), a human monoclonal antibody that targets the Notch2 and Notch3 receptors that is in Phase II clinical trials; Brontictuzumab (Anti-Notch1, OMP-52M51), a human monoclonal antibody, which completed single-agent Phase I trial for the treatment of solid tumor; and Vantictumab ((Anti-Fzd7, OMP-18R5) that completed a Phase I single-agent trial in tumor patients. Its products also include Ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based Frizzled8 receptor or Fzd8, which is in Phase I single agent trial; Wnt biologic #3, an additional bispecific biologic product candidate in preclinical studies; Wnt small molecule inhibitors, which is in preclinical testing; and RSPO-LGR, a CSC pathway that is in preclinical study of antibodies. OncoMed Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline LLC to develop anti-CSC antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

108 Employees
Last Reported Date: 03/12/15
Founded in 2004

oncomed pharmaceuticals inc (OMED) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $628.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $487.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $452.4K
Vice President and General Counsel
Total Annual Compensation: $383.8K
Compensation as of Fiscal Year 2013.

oncomed pharmaceuticals inc (OMED) Key Developments

OncoMed Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

OncoMed Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company's total revenues were $8.515 million compared to $18.983 million a year ago, primarily due to a $15 million payment from Bayer achieved in the fourth quarter of 2013 associated with a dose escalation milestone for the ipafricept (FZD8-Fc, OMP-54F28) program. Loss from operations was $15.624 million compared to $2.406 million a year ago. Net loss before provision for income taxes was $15.602 million compared to $2.399 million a year ago. Net loss was $15.056 million or $0.50 per basic and diluted share compared to $4.343 million or $0.15 per basic and diluted share a year ago. For the year, the company's total revenues were $39.559 million compared to $37.779 million a year ago. The year-over-year increase was driven by increased amortization of upfront payments due to a full year of revenue recognition for the 2013 Celgene transaction, partially offset by lower milestone payments versus the prior year. Loss from operations was $50.624 million compared to $23.899 million a year ago. Net loss before provision for income taxes was $50.519 million compared to $24.127 million a year ago. Net loss was $50.010 million or $1.69 per basic and diluted share compared to $26.071 million or $1.93 per basic and diluted share a year ago. The change in net loss for the year was due to an increase of collaboration revenue, more than offset by an increase in operational expenses, primarily research and development costs.

OncoMed Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 12, 2015

OncoMed Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 12, 2015

OncoMed Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 12, 2015

OncoMed Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMED:US $25.92 USD +0.14

OMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMED.
View Industry Companies
 

Industry Analysis

OMED

Industry Average

Valuation OMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.4x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOMED PHARMACEUTICALS INC, please visit www.oncomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.